Immuno-Oncology IHC marker
LAG3 (Lymphocyte activation gene-3, CD223) plays an important role in modulating T cell expansion and function. Interestingly, LAG-3 bears structural homology to CD4 and functions as a cell surface molecule expressed on activated T cells. Blockade of LAG-3 can augment T cell function. Moreover, several preclinical and clinical studies suggest a role for LAG-3 blocking antibodies in cancer immunotherapy.
TIM3 (T cell immunoglobulin and mucin-domain containig-3) also called HAVCR2 (hepatitis A viruis cellular receptor 2) was first identified as a protein selectively expressed on CD4+ and CD8+ T cells. TIM-3 is also expressed on other types of immun cells, including B cells, Tregs, NK cells, DCs, monocytes, and macrophages indicating an important role for immune response. Different preclinal studies have shown a therapeutic benefit of TIM3 blockade by regulating TME and restricting tumor groth especially in combination with PD-1 blockade.
The complexity of the TIGIT axis in immune oncology has increased the demand for different antibody clones targeting different immunogenic motifs.
CD226 and TIGIT share ligands and binding of CD155 and CD112 has different impact on T cell responses. This complexity may be investigated with different antibody clones targeting different immunogenic motifs.
Immuno-Oncology IHC marker
The unique clone R12 combines high specificity with high signal to noise ratio for immunohiostochemical detection of CD112R in human tissues. Therefore, clone R12 is ideally suited for multicolor immunofluorescence (fluorescence multiplex IHC) applications. CD112R is preferentially expressed on T-cells and inhibits T-cell receptor mediated signals. Blockade of the CD112R-CD112 interaction enhances T cell response.
Clone TG1 immunohistochemistry allows the identification of invading TIGIT positive T-cells in routine fixed FFPE human tumor tissues.
Clone FX3 has been developed and validated for fluorescence multiplex IHC studies of FOXP3 expression in human tissues. FOXP3 (Forkhead box protein P3) is mainly expressed in Regulatory T (Treg) cells, a subset of CD4+ T-cells, that play a suppressive role in the immune system. Treg cells ensure immune homeostasis through their ability to suppress the activation and function of leukocytes. FOXP3 has emerged as a prominent target for the development of new immunotherapies for cancer and autoimmune diseases.
CD73, together with CD39, plays an important role in promoting immunosuppression through the pathway degrading ATP into adenosine, which has a significant effect on the tumor microenvironment. Theses cell surface enzymes have emerged as novel therapeutic targets to enhance antitumor immune responses across a wide range of tumors.
Tumor IHC marker
Anti-PSA clone HAM18 has been tested for sensitivity, specificity and prognostic significance on more than 20.000 tissues and stands for being the best validated anti-PSA clone.
Clone JAP16 has been validated for detection of p16 INK4 in routine fixed FFPE tissues with focus on gynecological pathology.